Question has been topic of heated discussion after Congress leader Navjot Sidhu claimed dietary changes helped his wife beat ...

The FDA will review an application to consider potential approval of Nubeqa plus androgen deprivation therapy for metastatic ...

The FDA accepted a supplemental new drug application to darolutamide plus androgen deprivation therapy for metastatic ... In ...

When the drug binds to CD47, it helps destroy the cancer cells directly. In the study, magrolimab was combined with docetaxel, a type of chemotherapy. The study included 31 patients with metastatic ...

The FDA has accepted a supplemental new drug application for the combination of darolutamide and androgen deprivation therapy for the treatment of patients with metastatic hormone-sensitive prostate ...

Bayer (BAYRY) announced that the FDA has accepted the company’s supplemental new drug application, or sNDA, for the oral androgen receptor ...

The expansion in indications comes after the company’s Phase III trial saw the treatment extending survival in patients with ...

On International Men's Day, the Clinical Trials Arena team investigates three therapies being investigated in prostate cancer ...

The Prescription Drug User Fee Act date refers to the deadline set by the FDA for reviewing a NDA or Biologics License Application.

[83] For patients who have been pretreated with docetaxel, there are currently three therapeutic options: cabazitaxel, abiraterone and enzalutamide. All these three drugs have been demonstrated to ...

The treatment landscape for patients with prostate cancer, especially individuals with advanced disease, has dramatically ...

Following mixed study results, the partners have backed away from seeking broad clearance of dato-dxd in lung cancer and ...